Piper Jaffray Upgrades Pacific Biosciences of California (PACB) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pacific Bio (PACB) Q3 Revenue Misses Estimates
October 22, 2015 5:12 PM EDTPacific Bio (NASDAQ: PACB) reported Q3 EPS of $0.02, may not compare to the analyst estimate of ($0.27). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $15.84 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
... More